Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
10. U.S. Pot Stocks Are Heating Up and This Lesser-Known Cannabis Name Looks Poised to Catapult to the Top
Many Investors Placed Their Bets on the Illinois Cannabis Market, But Michigan is Now Surging, and When All is Said and Done, the Great Lakes State Could Be the Come Behind Winner
By September 2020, Michigan will generate $390 million in adult-use sales and nearly $1.5 billion by the end of 2021 before maturing into a $3 billion industry over the next few years. An effective combo of being in the right place, at the right time, with the right people has seen burgeoning multi-state operator (MSO), Red White & Bloom (OTCQX: RWBYF) establish a dominant 22% market share in Michigan’s cannabis market.
READ FULL RWB MICHIGAN ARTICLE
9. Will Cannabis Entrepreneurs Switch to Psychedelics?
The Psychedelics Space is Heating Up, and Major Players Have Taken Notice
The market is bolstered by a growing number of Psychedelics reform movements across the U.S., as well as an increasing number of market participants, including names like Champignon Brands (OTCQB: SHRMF), Hollister (OTC: HSTRF) and Revive Therapeutics (OTCPK: RVVTF). Cannabis firms and notable sector leaders are joining the market. Notable names include former Canopy Growth (NYSE: CGC) CEO Bruce Linton, now a director at MindMed (OTCQB: MMEDF) and chairman of the advisory board for Red Light Holland (CSE: TRIP).
READ FULL PSYCHEDELICS INVESTING ARTICLE
8. American Cannabis Operator Stocks Soar 27% in July
Adding to a 29% Gain in Q2 Despite a Pullback in June, the American Cannabis Operator Index Rocketed Higher in July, Increasing 26.7%
The four best performing Cannabis Stocks included Planet 13 (OTCQX: PLNHF), cbdMD (NYSE American: YCBD), TerrAscend (OTCQX: TRSSF) and Curaleaf (OTCQX: CURLF).
READ FULL U.S. OPERATORS ARTICLE
7. Totally Out There: Our Top 5 Psychedelic Stocks
As Cannabis Investors Increasingly Cross Over to the Psychedelic Side of the Aisle, the Race is on to See Which Company Will Be the Leader
Here are the top 5 Psychedelic Stocks as measured by market cap:
READ FULL TOP 5 PSYCHEDELIC STOCKS
6. Aleafia Health Launches Same-Day, Direct-to-Door Medical Cannabis Delivery
Previously, Aleafia’s Service Offered Next-Day Delivery Only
Aleafia Health’s (OTCQX: ALEAF) AssureHome Delivery, the industry-leading direct-to-door medical cannabis service, has now launched same-day delivery.
READ FULL ALEAFIA HEALTH ARTICLE
5. 3 Psychedelic Stocks for Healthcare Investors
Psychedelic Stocks Aren’t Yet Getting Cannabis-Level Attention, But There Interesting Opportunities Here
Yes, there’s some credibility to psychedelics and, potentially, investment rewards. Here are a few Psychedelic Stocks to consider.
READ FULL PSYCHEDELIC STOCKS ARTICLE
4. Red White & Bloom Exercises Call Option to Acquire 100% of Michigan-Based PharmaCo
Following the Acquisition’s Close, Red White & Bloom’s Financials Will Be Consolidated Under the Umbrella of the Public Company
Red White & Bloom (OTCQX: RWBYF) announced Monday that it officially provided notice of its intent to exercise the company’s option to acquire 100% of Michigan-based PharmaCo.
READ FULL RED WHITE & BLOOM ARTICLE
3. MindMed Completes Dosing 18-MC Phase 1 Study
MindMed, Seeing Early Success, Will Advance Preparations for a Phase 2a Clinical Trial in Opioid Addiction
MindMed (OTCQB: MMEDF) has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC. The dosing of 18-MC was well tolerated in humans and will help advance planning for a Phase 2a clinical trial in opioid addiction.
READ FULL MINDMED ARTICLE
2. Aphria: PI Financial Raises Price Target, Canaccord Reiterates Target
Last Week, Aphria Reported Year-End and Q4 Earnings Featuring Q4 Net Revenue of CDN $152.2 Million and EBITDA of CDN $8.6 Million
PI Financial reiterated its buy recommendation on Aphria (NYSE: APHA) and upgraded its 12-month price target from CDN $8 to CDN $12. Canaccord reiterated their 12-month price target of CDN $10, or a 56.5% upside while keeping its speculative buy recommendation.
READ FULL APHRIA ARTICLE
1. Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19
The Phase 3 Clinical Study Titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, Will Enroll Up to 1,000 Patients
Revive Therapeutics (OTCPK: RVVTF) announced that the U.S. Food & Drug Administration (FDA) has approved the company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
READ FULL REVIVE THERAPEUTICS ARTICLE
Photo by Rick Proctor on Unsplash
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.